NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition

Core Viewpoint - NKGen Biotech, Inc. is actively participating in the 7th China International Biotechnology Conference & Exhibition, showcasing its innovative NK cell therapeutics, particularly focusing on the treatment of neurodegenerative diseases like Alzheimer's and Parkinson's [1][2][3] Company Overview - NKGen is a clinical-stage biotechnology company based in Santa Ana, California, specializing in the development and commercialization of autologous and allogeneic natural killer (NK) cell therapeutics [6] - The company is developing a novel cell-based immunotherapeutic drug candidate named troculeucel, aimed at treating neurodegenerative disorders and various cancers [5] Conference Participation - Paul Y. Song, M.D., the CEO of NKGen, will present at BIOTEC-CHINA 2025, discussing the use of troculeucel for Alzheimer's and Parkinson's diseases [1][3] - The presentation will highlight promising results from Phase 1 clinical trials and ongoing Phase 1/2a trials for moderate Alzheimer's disease, with favorable clinical outcomes and biomarker data [3] Product Details - Troculeucel is recognized as the International Nonproprietary Name (INN) for SNK01, marking a significant milestone in NKGen's journey to market [5] - The therapy is designed to be patient-specific and is expanded ex vivo, indicating a tailored approach to immunotherapy [5]